Nevertheless, the potential anti-tumour activity of ErbB family inhibition in patients with solid tumours has been at the focus of interest: Dacomitinib and HKI272 are the two most promising drugs that have reached phase III trials in patients with EGFR-mutated NSCLC and HER2neu positive breast cancer, respectively [35, 36]. The gene discussed is EGFR; the disease is neoplasm.